In recent years, potential uses and therapeutic benefits of polymer anticancer therapeutics are enormous. Over the past decades, cancer is one of the leading causes of mortality in the world. Many clinically approved chemotherapeutics severely encountering potential challenges against deadly cancer. Moreover, safetyand efficacy of anticancer agents have been limited by undesirable pharmacokinetics and biodistribution in the body.To address these limitations, various polymer drug conjugations are being studied and developed to improve the antitumor efficacy. Among other therapeutics, polymer therapeutics are well established platforms that circumvent anticancer therapeutics from enzymatic metabolism via direct conjugation to therapeutic molecules. Interestingly, polymer therapeutics will meet an unmet need of small molecules. The knowledge is thatpolymer-drug conjugation can achieve desired pharmacokinetics and biodistribution propertiesof several anticancer drugs. The present review mainly enlightens the most recent preclinical and clinical studies include safety, stability, pharmacokinetic behavior and distribution of polymer therapeutics.